Global Parkinson’s Disease Therapeutics Market 2018 : Industry Overview, Sales, Demand, Analysis, Opportunities and Forecast to 2025

 Published: Oct-2018 |  Format: PDF | Qy Research |  Number of pages: 110

<pre>Parkinson's disease is a type of progressive movement disorder, characterized by muscle rigidity, and tremors.  In 2017, the global Parkinson’s Disease Therapeutics market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Parkinson’s Disease Therapeutics market based on company, product type, application and key regions. This report studies the global market size of Parkinson’s Disease Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Parkinson’s Disease Therapeutics in these regions. This research report categorizes the global Parkinson’s Disease Therapeutics market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis. The various contributors involved in the value chain of Parkinson’s Disease Therapeutics include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Parkinson’s Disease Therapeutics include Abbvie, Inc. Biogen, Inc. Boehringer Ingelheim GmbH F. Hoffman-La Roche GlaxoSmithKline Plc. H. Lundbeck A/S Impax Labs, Inc. Newron Pharmaceuticals SpA Novartis AG Orion Corporation Teva Pharmaceutical Industries Ltd. UCB S.A. Market Size Split by Type Oral Transdermal Subcutaneous Intestinal Infusion Market Size Split by Application Hospitals Clinics Others Market size split by Region North America United States Canada Mexico Asia-Pacific China India Japan South Korea Australia Indonesia Singapore Malaysia Philippines Thailand Vietnam Europe Germany France UK Italy Spain Russia Central & South America Brazil Rest of Central & South America Middle East & Africa GCC Countries Turkey Egypt South Africa The study objectives of this report are: To study and analyze the global Parkinson’s Disease Therapeutics market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025. To understand the structure of Parkinson’s Disease Therapeutics market by identifying its various subsegments. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). Focuses on the key global Parkinson’s Disease Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Parkinson’s Disease Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market. To project the value and volume of Parkinson’s Disease Therapeutics submarkets, with respect to key regions (along with their respective key countries). To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. To strategically profile the key players and comprehensively analyze their growth strategies. In this study, the years considered to estimate the market size of Parkinson’s Disease Therapeutics are as follows: History Year: 2013-2017 Base Year: 2017 Estimated Year: 2018 Forecast Year 2018 to 2025 This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Parkinson’s Disease Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources. For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.</pre>
<pre>Table of Contents 1 Study Coverage 1.1 Parkinson’s Disease Therapeutics Product 1.2 Key Market Segments 1.3 Key Manufacturers Covered 1.4 Market by Type 1.4.1 Global Parkinson’s Disease Therapeutics Market Size Growth Rate by Type 1.4.2 Oral 1.4.3 Transdermal 1.4.4 Subcutaneous 1.4.5 Intestinal Infusion 1.5 Market by Application 1.5.1 Global Parkinson’s Disease Therapeutics Market Size Growth Rate by Application 1.5.2 Hospitals 1.5.3 Clinics 1.5.4 Others 1.6 Study Objectives 1.7 Years Considered 2 Executive Summary 2.1 Global Parkinson’s Disease Therapeutics Market Size 2.1.1 Global Parkinson’s Disease Therapeutics Revenue 2016-2025 2.1.2 Global Parkinson’s Disease Therapeutics Sales 2016-2025 2.2 Parkinson’s Disease Therapeutics Growth Rate by Regions 2.2.1 Global Parkinson’s Disease Therapeutics Sales by Regions 2.2.2 Global Parkinson’s Disease Therapeutics Revenue by Regions 3 Breakdown Data by Manufacturers 3.1 Parkinson’s Disease Therapeutics Sales by Manufacturers 3.1.1 Parkinson’s Disease Therapeutics Sales by Manufacturers 3.1.2 Parkinson’s Disease Therapeutics Sales Market Share by Manufacturers 3.1.3 Global Parkinson’s Disease Therapeutics Market Concentration Ratio (CR5 and HHI) 3.2 Parkinson’s Disease Therapeutics Revenue by Manufacturers 3.2.1 Parkinson’s Disease Therapeutics Revenue by Manufacturers (2016-2018) 3.2.2 Parkinson’s Disease Therapeutics Revenue Share by Manufacturers (2016-2018) 3.3 Parkinson’s Disease Therapeutics Price by Manufacturers 3.4 Parkinson’s Disease Therapeutics Manufacturing Base Distribution, Product Types 3.4.1 Parkinson’s Disease Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Parkinson’s Disease Therapeutics Product Category 3.4.3 Date of International Manufacturers Enter into Parkinson’s Disease Therapeutics Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type 4.1 Global Parkinson’s Disease Therapeutics Sales by Type 4.2 Global Parkinson’s Disease Therapeutics Revenue by Type 4.3 Parkinson’s Disease Therapeutics Price by Type 5 Breakdown Data by Application 5.1 Overview 5.2 Global Parkinson’s Disease Therapeutics Breakdown Data by Application 6 North America 6.1 North America Parkinson’s Disease Therapeutics by Countries 6.1.1 North America Parkinson’s Disease Therapeutics Sales by Countries 6.1.2 North America Parkinson’s Disease Therapeutics Revenue by Countries 6.1.3 United States 6.1.4 Canada 6.1.5 Mexico 6.2 North America Parkinson’s Disease Therapeutics by Type 6.3 North America Parkinson’s Disease Therapeutics by Application 6.4 North America Parkinson’s Disease Therapeutics by Company 7 Europe 7.1 Europe Parkinson’s Disease Therapeutics by Countries 7.1.1 Europe Parkinson’s Disease Therapeutics Sales by Countries 7.1.2 Europe Parkinson’s Disease Therapeutics Revenue by Countries 7.1.3 Germany 7.1.4 France 7.1.5 UK 7.1.6 Italy 7.1.7 Russia 7.2 Europe Parkinson’s Disease Therapeutics by Type 7.3 Europe Parkinson’s Disease Therapeutics by Application 7.4 Europe Parkinson’s Disease Therapeutics by Company 8 Asia Pacific 8.1 Asia Pacific Parkinson’s Disease Therapeutics by Countries 8.1.1 Asia Pacific Parkinson’s Disease Therapeutics Sales by Countries 8.1.2 Asia Pacific Parkinson’s Disease Therapeutics Revenue by Countries 8.1.3 China 8.1.4 Japan 8.1.5 Korea 8.1.6 India 8.1.7 Australia 8.1.8 Indonesia 8.1.9 Malaysia 8.1.10 Philippines 8.1.11 Thailand 8.1.12 Vietnam 8.1.13 Singapore 8.2 Asia Pacific Parkinson’s Disease Therapeutics by Type 8.3 Asia Pacific Parkinson’s Disease Therapeutics by Application 8.4 Asia Pacific Parkinson’s Disease Therapeutics by Company 9 Central & South America 9.1 Central & South America Parkinson’s Disease Therapeutics by Countries 9.1.1 Central & South America Parkinson’s Disease Therapeutics Sales by Countries 9.1.2 Central & South America Parkinson’s Disease Therapeutics Revenue by Countries 9.1.3 Brazil 9.2 Central & South America Parkinson’s Disease Therapeutics by Type 9.3 Central & South America Parkinson’s Disease Therapeutics by Application 9.4 Central & South America Parkinson’s Disease Therapeutics by Company 10 Middle East and Africa 10.1 Middle East and Africa Parkinson’s Disease Therapeutics by Countries 10.1.1 Middle East and Africa Parkinson’s Disease Therapeutics Sales by Countries 10.1.2 Middle East and Africa Parkinson’s Disease Therapeutics Revenue by Countries 10.1.3 GCC Countries 10.1.4 Turkey 10.1.5 Egypt 10.1.6 South Africa 10.2 Middle East and Africa Parkinson’s Disease Therapeutics by Type 10.3 Middle East and Africa Parkinson’s Disease Therapeutics by Application 10.4 Middle East and Africa Parkinson’s Disease Therapeutics by Company 11 Company Profiles 11.1 Abbvie, Inc. 11.1.1 Abbvie, Inc. Company Details 11.1.2 Company Description 11.1.3 Sales, Revenue and Gross Margin of Parkinson’s Disease Therapeutics 11.1.4 Parkinson’s Disease Therapeutics Product Description 11.1.5 Recent Development 11.2 Biogen, Inc. 11.2.1 Biogen, Inc. Company Details 11.2.2 Company Description 11.2.3 Sales, Revenue and Gross Margin of Parkinson’s Disease Therapeutics 11.2.4 Parkinson’s Disease Therapeutics Product Description 11.2.5 Recent Development 11.3 Boehringer Ingelheim GmbH 11.3.1 Boehringer Ingelheim GmbH Company Details 11.3.2 Company Description 11.3.3 Sales, Revenue and Gross Margin of Parkinson’s Disease Therapeutics 11.3.4 Parkinson’s Disease Therapeutics Product Description 11.3.5 Recent Development 11.4 F. Hoffman-La Roche 11.4.1 F. Hoffman-La Roche Company Details 11.4.2 Company Description 11.4.3 Sales, Revenue and Gross Margin of Parkinson’s Disease Therapeutics 11.4.4 Parkinson’s Disease Therapeutics Product Description 11.4.5 Recent Development 11.5 GlaxoSmithKline Plc. 11.5.1 GlaxoSmithKline Plc. Company Details 11.5.2 Company Description 11.5.3 Sales, Revenue and Gross Margin of Parkinson’s Disease Therapeutics 11.5.4 Parkinson’s Disease Therapeutics Product Description 11.5.5 Recent Development 11.6 H. Lundbeck A/S 11.6.1 H. Lundbeck A/S Company Details 11.6.2 Company Description 11.6.3 Sales, Revenue and Gross Margin of Parkinson’s Disease Therapeutics 11.6.4 Parkinson’s Disease Therapeutics Product Description 11.6.5 Recent Development 11.7 Impax Labs, Inc. 11.7.1 Impax Labs, Inc. Company Details 11.7.2 Company Description 11.7.3 Sales, Revenue and Gross Margin of Parkinson’s Disease Therapeutics 11.7.4 Parkinson’s Disease Therapeutics Product Description 11.7.5 Recent Development 11.8 Newron Pharmaceuticals SpA 11.8.1 Newron Pharmaceuticals SpA Company Details 11.8.2 Company Description 11.8.3 Sales, Revenue and Gross Margin of Parkinson’s Disease Therapeutics 11.8.4 Parkinson’s Disease Therapeutics Product Description 11.8.5 Recent Development 11.9 Novartis AG 11.9.1 Novartis AG Company Details 11.9.2 Company Description 11.9.3 Sales, Revenue and Gross Margin of Parkinson’s Disease Therapeutics 11.9.4 Parkinson’s Disease Therapeutics Product Description 11.9.5 Recent Development 11.10 Orion Corporation 11.10.1 Orion Corporation Company Details 11.10.2 Company Description 11.10.3 Sales, Revenue and Gross Margin of Parkinson’s Disease Therapeutics 11.10.4 Parkinson’s Disease Therapeutics Product Description 11.10.5 Recent Development 11.11 Teva Pharmaceutical Industries Ltd. 11.12 UCB S.A. 12 Market Opportunities, Challenges, Risks and Influences Factors Analysis 12.1 Market Opportunities and Drivers 12.2 Market Challenges 12.3 Market Risks/Restraints 12.4 Key World Economic Indicators 13 Value Chain and Sales Channels Analysis 13.1 Value Chain Analysis 13.1.1 Typical Suppliers of Key Parkinson’s Disease Therapeutics Raw Material 13.1.2 Parkinson’s Disease Therapeutics Customers 13.2 Sales Channels Analysis 13.2.1 Sales Channels Analysis 13.2.2 Distributors 14 Research Findings and Conclusion 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.1.1 Research Programs/Design 15.1.1.2 Market Size Estimation 15.1.1.3 Market Breakdown and Data Triangulation 15.1.2 Data Source 15.1.2.1 Secondary Sources 15.1.2.2 Primary Sources 15.2 Author Details 15.3 Disclaimer</pre>
Please submit the below form, to get more about this report:
Indicates required fields

Please fill your details below, to receive sample report:
Indicates required fields



Latest News

Jan-2018 |Electrical & Electronic

Study Claims That Mobile Apps Enhance Mental Health Thus Fueling The Global Smartphone Application Market

People undergoing mental health issues can reinforce their psychological well-being via mobile apps, a new survey claimed. The study, posted in the journal JMIR Mental Health, claimed that users who grapple with emotional and mental health issues ...

Jan-2018 |Medical & Health

Government Controlling Drugs And Prices Impacting Pharmaceuticals Market

The central government is preparing to curb the prices of combine drugs, which include 14 types of drugs. These drugs are used in the treatment of diseases such as high blood pressure, sugar, and cholesterol. The Nationa ...

Jan-2018 |ICT and Media

Two lakh Job In IT Sector Depicting Solid Growth In The Market

Last year, there was little interference for jobs in India but the scenario of jobs looks better in 2018. This year, there is hope for more than two lakh jobs in the information technology sector.

According to data, the Indian employment ...

Jan-2018 |Automobile

The Key Drivers Of The Automobile Market Are Tier-I, Iii Cities

The automobile industry despite various obstacles such as demonetization and GST has rapidly grabbed its momentum in this fiscal and has reported the growth of 9–10% compared to 7–8% in the last fiscal. This report was presented by Soc ...

Jan-2018 |Electrical & Electronic

Indian Smartphone Market Expected To Heat Up By Amazon With 10.or

Retailer Amazon is planning to introduce a smartphone range in the Indian market under a brand 10.or. This move is to take over the India-based rival, Flipkart.

The smartphones, which is expected to on sale on January 5 will be introduce ...